What is ARQT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 4.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ARQT?

P/E (TTM) is 139.89 and 52-week range is $19.30 to $33.30 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ARQT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ARQT?

The company profile lists revenue (TTM) near $429M, net income (TTM) near $26M, EPS (TTM) near $0.21 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Arcutis Biotherapeutics, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Westlake Village, California, US, 125.7M shares outstanding, ISIN US03969K1088 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Arcutis Biotherapeutics, Inc.

$ARQT

Health Care · Biotechnology

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 354 full-time employees. The company went IPO on 2020-01-31. The firm develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.

Employees

354

Website

arcutis.com/

IPO

2020-01-31

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US03969K1088

Headquarters

Westlake Village, California, US

Shares outstanding

125.7M

NAICS sector

Manufacturing

Institutional ownership

98.94%

Browse other companiesFree AI scores and summaries for more stocks